AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Palmitoleoyl-protein carboxylesterase NOTUM

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q6P988

UPID:

NOTUM_HUMAN

Alternative names:

hNOTUM

Alternative UPACC:

Q6P988; Q8N410; Q8NI82

Background:

Palmitoleoyl-protein carboxylesterase NOTUM, also known as hNOTUM, plays a pivotal role in the Wnt signaling pathway. It acts as a key negative regulator by mediating the depalmitoleoylation of WNT proteins, which is crucial for their binding to frizzled receptors. This process is essential for the proper functioning of the Wnt pathway, a critical regulator of cell fate determination, proliferation, and migration.

Therapeutic significance:

Understanding the role of Palmitoleoyl-protein carboxylesterase NOTUM could open doors to potential therapeutic strategies. Its unique function in the Wnt signaling pathway makes it a promising target for drug discovery, aiming to modulate this pathway in various diseases where it is implicated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.